We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




New Insights Into Fetal DNA Could Improve Non-Invasive Prenatal Testing

By LabMedica International staff writers
Posted on 06 Oct 2026

Non-invasive prenatal testing is widely used to screen pregnancies for genetic conditions by analyzing DNA fragments in maternal blood. More...

Although it offers a safer alternative to invasive procedures such as amniocentesis, high-risk results still require confirmatory testing and can produce false alarms. Researchers now present new insights into how fetal DNA circulates in maternal blood, which could support improvements in prenatal screening.

Researchers at Adelaide University led an international review of decades of research on fetal DNA in maternal circulation. The work focuses on non-invasive prenatal testing (NIPT), which analyzes small DNA fragments from the placenta that circulate in the mother’s bloodstream. Since its introduction in 2011, millions of women worldwide have used NIPT, and about 30% of families in Australia choose to pay around A$500 for the test, often out of pocket.

The researchers highlight that NIPT still has important limitations despite its widespread adoption. If NIPT indicates high risk for a chromosomal condition, parents may wait more than a month for confirmation and undergo an invasive diagnostic procedure. High-risk NIPT results are rare, but 47% of such results are described as false alarms.

To better understand how fetal DNA moves through maternal blood, the researchers examined its origins, how it enters the bloodstream, and what structures may carry it once it is circulating. They challenged long-held assumptions about fetal DNA and highlighted unresolved questions about the exact placental cell types that release it. They also considered whether fetal DNA travels attached to extracellular vesicles or other molecular structures.

The paper, titled “Reappraising the topology of cell-free fetal DNA in maternal blood towards improved prenatal genetic diagnostics,” was published in Science Advances. The collaborating team was led by Adelaide University and included the Future Industries Institute. The researchers concluded that understanding the origin and structure of fetal DNA could help increase the fetal fraction available for testing, which they identify as a major challenge for current prenatal screening technologies.

“Science and technology have advanced rapidly, but our biological understanding of fetal DNA has not kept pace. By uncovering the fundamental biology of fetal DNA, we can create new tools that make prenatal testing more reliable, more comprehensive and potentially more affordable,” said Professor Benjamin Thierry, Director of the Precision Nanomedicine Program at Adelaide University.

Related Links
Adelaide University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.